Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 6, 2022; 10(4): 1454-1456
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1454
Rituximab as a treatment for human immunodeficiency virus-associated nemaline myopathy: What does the literature have to tell us?
Jucier Gonçalves Júnior, Samuel Katsuyuki Shinjo
Jucier Gonçalves Júnior, Samuel Katsuyuki Shinjo, Division of Rheumatology, São Paulo University, São Paulo 01246-903, Brazil
Author contributions: The authors contributed equally to all aspects of this manuscript preparation and have read and approved the final manuscript; Each author meets the criteria for authorship established by the International Committee of Medical Journal Editors.
Conflict-of-interest statement: The author declare they do not have conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jucier Gonçalves Júnior, MD, Academic Research, Division of Rheumatology, São Paulo University, Av. Dr. Arnaldo 3184, 3º Andar-Sala 3131 Cerqueira César, São Paulo 01246-903, Brazil. juciergjunior@hotmail.com
Received: August 12, 2021
Peer-review started: August 12, 2021
First decision: October 20, 2021
Revised: November 13, 2021
Accepted: December 31, 2021
Article in press: December 31, 2021
Published online: February 6, 2022
Core Tip

Core Tip: Rituximab may be a therapeutic possibility for the treatment of nemaline myopathies (e.g., human immunodeficiency virus-associated and monoclonal gammopathy of undetermined significance-associated) because it is less aggressive and has fewer side effects compared to current therapies. It may be especially helpful in cases of severe visceral involvement. However, the cost and unavailability of therapy can be a limiting factor.